Privo Technologies, 200 Corporate Place Suite 6B, Peabody, MA (2025)

09/10/2022

So proud of my team for this Nature Communciations publication. Great work Privo !!!!

Nature Communications Publication on SCC Tumor Response to PRV111

Privo Technologies Inc. is excited to announce its Nature Communications publication https://lnkd.in/eNs-5UMK titled "A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in patients and animal models.

Privo’s lead oncology asset, PRV111, a self-adhesive cisplatin loaded patch system designed for topical and local chemotherapy treatment on mucosal cancers to eliminate cancer cells in the tumor and regional lymph nodes. In this study we first examine safety and efficacy of the PRV111 using several well-established animal models, followed by a phase I/II clinical trial targeting T1/T2 oral squamous cell carcinoma designed to improve efficacy and reduce toxicity in patients with resectable oral cancer by local administration of PRV111.

The data from this paper provides validation of our platform for nano-encapsulating highly potent drugs while providing controlled delivery and release. Privo is excited to add to the growing body of scientific evidence demonstrating that encapsulation for local delivery of highly toxic chemotherapies and other drug classes can unlock therapeutic benefits, disrupting the targeted drug delivery industry both topically and intraoperatively.

This study is a result of collaborative efforts between Privo Technologies Inc, and the head and neck cancer group at the UChicago Medicine. We are also thankful to scientists, researchers, and clinicians from several academic institutions who supported this study. Click here to access the full press release:
https://lnkd.in/eYnHHXSQ

Many thanks to our wonderful scientific advisors especially Dr. Nishant Agrawal and Dr. Evgeny Izumchenko. This would not be possible without you. Special thanks to Aaron Manzi, Stefanie Cantin, Peter Conway, and Benjamin Flaum. Great Job!!!!
https://www.nature.com/articles/s41467-022-31859-3

#

Cisplatin is the most frequently used chemotherapeutic agent for the treatment of patients with oral cavity squamous cell carcinoma (OCSCC), however, systemic administration is often associated with dose limiting side effects. Here the authors design and test a nano-engineered patch system (PRV111)....

09/10/2022

Privo Technologies, Inc Receives its 3rd U.S. FDA Orphan Drug Designation
We are very pleased to announce that Privo has received Orphan Drug Designation (ODD) from the FDA for the treatment of oral carcinoma in situ (CIS).

The Agency has granted ODD to Privo's PRV111 asset for the treatment of accessible CIS of the oral cavity. This is Privo's and PRV111's third such ODD to date, adding to a portfolio of ODDs for accessible invasive oral cavity cancers and a**l cancer.

"Achieving this important regulatory milestone means we are one step closer to bringing new treatment options to patients diagnosed with oral CIS," said Manijeh Goldberg, Ph.D., CEO. "The standard of care currently is surgery, resulting in severe disfigurement and poor quality of life. Our novel transmucosal delivery system with embedded cisplatin-loaded nanoparticles, PRV111, allows for patients to be treated with topical chemotherapy providing an alternative to surgery that effectively treats cancer while maintaining the form and function of the oral cavity."

ODD provides benefits to drug developers creating treatments for underserved groups. These benefits include tax credits for clinical costs, exemption from FDA PDUFA fees, and seven years of post-approval exclusivity.

/PRNewswire/ -- Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to...

09/10/2022

Very excited to share the Forbes article about Privo Technologies Inc and its disruptive platform technology for safely treating cancer patients. Thanks to our wonderful Privo team, our brilliant advisor and board member, James Mackay, and our clinical collaborators at UChicago Medicine for their support and belief in our mission: "Tough on Cancer, Easy on Patients".

The article, titled "Going beyond target or mechanism of disease disruptive innovation in drug delivery systems" talks about innovative research led by a team of investigators from Privo Technologies Inc and UChicago Medicine and describes how this work may revolutionize the treatment of head and neck cancer.
https://www.forbes.com/sites/alexzhavoronkov/2022/09/07/going-beyond-target-or-mechanism-of-disease-disruptive-innovation-in-drug-delivery-systems/?sh=4c4aa2eb6658

Identifying novel targets and designing novel molecules is not the only way to innovate in the biopharmaceutical industry. Sometimes, innovation in delivery systems for well-know and established therapeutics may be just as disruptive as the new targeted medicine.

09/05/2022

Privo Technologies, Inc Receives its 3rd U.S. FDA Orphan Drug Designation
We are very pleased to announce that Privo has received Orphan Drug Designation (ODD) from the FDA for the treatment of oral carcinoma in situ (CIS).

The Agency has granted ODD to Privo's PRV111 asset for the treatment of accessible CIS of the oral cavity. This is Privo's and PRV111's third such ODD to date, adding to a portfolio of ODDs for accessible invasive oral cavity cancers and a**l cancer.

"Achieving this important regulatory milestone means we are one step closer to bringing new treatment options to patients diagnosed with oral CIS," said Manijeh Goldberg, Ph.D., CEO. "The standard of care currently is surgery, resulting in severe disfigurement and poor quality of life. Our novel transmucosal delivery system with embedded cisplatin-loaded nanoparticles, PRV111, allows for patients to be treated with topical chemotherapy providing an alternative to surgery that effectively treats cancer while maintaining the form and function of the oral cavity."

ODD provides benefits to drug developers creating treatments for underserved groups. These benefits include tax credits for clinical costs, exemption from FDA PDUFA fees, and seven years of post-approval exclusivity.

Click here to access the full press release.https://https://lnkd.in/eyAW2qQx

09/05/2022

Privo Technologies Inc. is excited to announce its Nature Communications publication https://lnkd.in/eNs-5UMK titled "A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in patients and animal models.

Privo’s lead oncology asset, PRV111, a self-adhesive cisplatin loaded patch system designed for topical and local chemotherapy treatment on mucosal cancers to eliminate cancer cells in the tumor and regional lymph nodes. In this study we first examine safety and efficacy of the PRV111 using several well-established animal models, followed by a phase I/II clinical trial targeting T1/T2 oral squamous cell carcinoma designed to improve efficacy and reduce toxicity in patients with resectable oral cancer by local administration of PRV111.

The data from this paper provides validation of our platform for nano-encapsulating highly potent drugs while providing controlled delivery and release. Privo is excited to add to the growing body of scientific evidence demonstrating that encapsulation for local delivery of highly toxic chemotherapies and other drug classes can unlock therapeutic benefits, disrupting the targeted drug delivery industry both topically and intraoperatively.

This study is a result of collaborative efforts between Privo Technologies Inc, and the head and neck cancer group at the UChicago Medicine. We are also thankful to scientists, researchers, and clinicians from several academic institutions who supported this study. Click here to access the full press release:
https://lnkd.in/eYnHHXSQ

Many thanks to our wonderful scientific advisors especially Dr. Nishant Agrawal and Dr. Evgeny Izumchenko. This would not be possible without you. Special thanks to Aaron Manzi, Stefanie Cantin, Peter Conway, and Benjamin Flaum. Great Job!!!!

#

Significant Tumor Reduction in one week with Privo's topical nanoengineered patch oral cancer

06/01/2021

02/23/2021

So proud of my team at Privo technologies for their creative and hard work which has led us to win the AIM-HI Women's Venture Competition.

Privo Technologies to Receive $900,000 of Investment Funding Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for…

01/16/2021

Privo Technologies is excited to announce that it has successfully completed its phase II oncology trial in head and neck cancer, meeting all endpoints and showing compelling safety and efficacy results. Privo, is currently preparing for its phase III clinical studies and is committed to effectively treat patients with solid tumors while significantly reducing side effects. Its lead products PRV111 and PRV211 will be studied in 2 phase III registration trials.